Ameriprise
EPZM

Ameriprise’s Epizyme, Inc EPZM Stock Holding History

Ameriprise’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-116,300
Closed -$1.46M – 3797
2019
Q2 		$1.46M Buy
+116,300
New +$1.5M ﹤0.01% 2911
2019
Q1 		– Sell
-10,950
Closed -$67K – 3799
2018
Q4 		$67K Buy
10,950
+30
+0.3% +$229 ﹤0.01% 3561
2018
Q3 		$116K Sell
10,920
-60
-0.5% -$685 ﹤0.01% 3614
2018
Q2 		$149K Sell
10,980
-110
-1% -$1.71K ﹤0.01% 3533
2018
Q1 		$196K Buy
+11,090
New +$187K ﹤0.01% 3489
2014
Q4 		– Sell
-35
Closed -$1K – 4579
2014
Q3 		$1K Sell
35
-20
-36% -$622 ﹤0.01% 5611
2014
Q2 		$2K Buy
+55
New +$1.29K ﹤0.01% 5244
2013
Q4 		– Sell
-369
Closed -$15K – 5482
2013
Q3 		$15K Hold
369
– – ﹤0.01% 4624
2013
Q2 		$10K Buy
+369
New +$9.48K ﹤0.01% 4791

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Ameriprise's EPZM Position: Q3 2019 in Review

Ameriprise sold out of Epizyme, Inc (EPZM) in Q3 2019, closing a stake of 116,300 shares — an estimated $1.46M sold.

Ameriprise first reported a position in EPZM in Q2 2013 and held it in 9 quarters. The position peaked at $1.46M in Q2 2019. 115 funds tracked by Wall St. Rank hold EPZM as of Q3 2019.

  • Ameriprise reported no remaining Epizyme, Inc position as of Q3 2019 after selling out during the quarter.
  • Ameriprise sold 116,300 Epizyme, Inc shares in Q3 2019, an estimated $1.46M.
  • Ameriprise first reported a position in Epizyme, Inc in Q2 2013 and held it in 9 quarters.
  • Ameriprise's Epizyme, Inc position peaked at $1.46M in Q2 2019.
  • 115 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2019.

Based on Ameriprise's 13F filing for Q3 2019, filed 14 Nov 2019.